RVL Pharmaceuticals plc is a pharmaceutical company focused on developing and commercializing eye care and medical aesthetics products. The Company is focused on developing and commercializing products for an underserved patient population in ocular medicine and medical aesthetics. It operates in one business segment which focuses on developing and commercializing pharmaceutical products. The Company is commercializing Upneeq for treating acquired blepharoptosis (low-lying eyelids) in adults and is developing Arbaclofen ER tablets for alleviating spasticity in multiple sclerosis patients. Their healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and other qualified practitioners. The target patient population comprises adults with droopy or low-lying eyelids, primarily females. Its commercial operations are managed by wholly owned subsidiaries, RVL Pharmaceuticals, Inc., and RVL Pharmacy, LLC.

Employees

125

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets Other stock markets 09:30:00 2026-06-09 EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-

05-01	Rvl Pharmaceuticals Launches Upneeq Reveal Under Eye Complex	CI
24-11-03	RVL Pharmaceuticals plc (OTCPK:RVLP.Q) cancelled the acquisition of acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc..	CI

Market Cap	334K 289K 266K 249K 467K 31.77M 474K 3.14M 1.22M 15.46M 1.25M 1.23M 53.54M	P/E Ratio 2021	-1.12x	P/E Ratio 2022	-1.95x
Enterprise Value	13.28M 11.47M 10.57M 9.89M 18.54M 1.26B 18.83M 125M 48.66M 614M 49.84M 48.78M 2.13B	EV / Sales 2021	5.55x	EV / Sales 2022	2.49x
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

05-01	Rvl Pharmaceuticals Launches Upneeq Reveal Under Eye Complex	CI
24-11-03	RVL Pharmaceuticals plc (OTCPK:RVLP.Q) cancelled the acquisition of acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc..	CI
24-10-28	RVL Pharmaceuticals plc (OTCPK:RVLP.Q) offered to acquire Assets of Avenova Brand and Business of NovaBay Pharmaceuticals, Inc. from NovaBay Pharmaceuticals, Inc. for $11.5 million.	CI
23-10-25	RVL Pharmaceuticals plc(NasdaqGS:RVLP) dropped from S&P TMI Index	CI
23-10-20	RVL Pharmaceuticals plc(NasdaqGS:RVLP) dropped from NASDAQ Composite Index	CI
23-10-12	Health Care Down as Risk Aversion Hurts Biotech -- Health Care Roundup	DJ
23-10-12	Top Midday Decliners	MT
23-10-12	RVL Pharmaceuticals Subsidiaries File for Prepackaged Chapter 11 Change of Control to Lenders	MT
23-09-29	Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	MT
23-09-29	Top Premarket Gainers	MT
23-09-22	RVL Pharmaceuticals plc Announces Resignation of Joaquin Benes and Juan Vergez from the Board of Directors	CI
23-08-21	HC Wainwright Adjusts RVL Pharmaceuticals Price Target to $3 From $4, Maintains Buy Rating	MT
23-08-16	Top Midday Decliners	MT

23-08-21	HC Wainwright Adjusts RVL Pharmaceuticals Price Target to $3 From $4, Maintains Buy Rating	MT
23-05-01	Barclays Adjusts Price Target on RVL Pharmaceuticals to $2 From $3, Keeps Overweight Rating	MT
22-10-25	Barclays Adjusts Price Target on RVL Pharmaceuticals to $3 From $4, Reiterates Overweight Rating	MT
22-10-21	Jefferies Assumes RVL Pharmaceuticals at Hold With $2.50 Price Target	MT
22-04-05	Barclays Reinstates RVL Pharmaceuticals at Overweight With $4 Price Target	MT

RVL Pharmaceuticals plc Stock

Stocks

RVLP.Q

IE00BF2HDL56

Biotechnology & Medical Research

Valuation: RVL Pharmaceuticals plc

Chart: RVL Pharmaceuticals plc

Latest news : RVL Pharmaceuticals plc

Analysts' recommendations: RVL Pharmaceuticals plc

Press Releases: RVL Pharmaceuticals plc

News in other languages: RVL Pharmaceuticals plc

Course Extremes

Managers and Directors: RVL Pharmaceuticals plc

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

24-05-20	RVL Pharmaceuticals - Upneeq Wins 2024 Shape Skin Award, 'Best for Lift', in the Professional Treatment Category	AQ
23-10-12	RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. Subsidiaries	AQ
23-08-25	RVL Pharmaceuticals : Regulation FD Disclosure - Form 8-K	PU
23-08-23	RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference	AQ
23-08-16	RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules	AQ

24-05-08	Relief Therapeutics réorganise entièrement sa direction
20-12-30	Emergent BioSolutions : MÄRKTE USA/Dow-Jones schließt mit kleinen Gewinnen auf Rekordhoch
20-12-30	Emergent BioSolutions : MÄRKTE USA/Börsen in ruhigem Geschäft leicht im Plus
20-12-30	Emergent BioSolutions : MÄRKTE USA/Börsen mit leichten Aufschlägen zum Start
20-12-30	Emergent BioSolutions : MARKT USA/Börsen mit moderaten Aufschlägen erwartet

Manager	Title	Age	Since
James Schaub COO	Chief Operating Officer	44	2015-12-31
Jarret Miller HRO	Human Resources Officer	-	2015-12-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-10-18	Altchem Ltd.	Sell	Company	14,122,659	12.6767%
23-10-18	Altchem Ltd.	Sell	Company	14,122,659	12.6767%
23-10-17	Altchem Ltd.	Sell	Company	3,421,537	3.0712%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RVL PHARMACEUTICALS PLC	0.00%	0.00%	-	-	111
LONZA GROUP AG	-0.35%	+0.97%	-13.80%	-13.83%	43.03B
REVOLUTION MEDICINES, INC.	+3.11%	+3.11%	+279.08%	+509.39%	32.71B
IQVIA HOLDINGS INC.	+0.22%	-1.08%	+15.66%	-14.70%	30.29B
BEONE MEDICINES AG	+1.62%	-2.08%	-1.91%	+27.08%	29.4B
CELLTRION, INC.	+4.09%	+0.93%	+12.97%	+20.66%	25.08B
ASCENDIS PHARMA A/S	+1.14%	+3.62%	-	-	13.54B
MEDPACE HOLDINGS, INC.	-1.63%	+2.88%	+56.69%	+114.08%	13.35B
EUROFINS SCIENTIFIC SE	-0.40%	-1.29%	+6.23%	+6.41%	12.97B
IONIS PHARMACEUTICALS, INC.	-0.74%	-1.62%	+105.89%	+79.51%	12.11B
Average	+0.71%	+1.30%	+57.60%	+91.07%	21.25B
Weighted average by Cap.	+1.05%	+1.48%	+57.30%	+98.05%

	2021	2022
Net sales	17.5M 15.12M 13.93M 13.04M 24.43M 1.66B 24.81M 164M 64.13M 810M 65.68M 64.28M 2.8B	49.72M 42.94M 39.57M 37.04M 69.42M 4.73B 70.49M 467M 182M 2.3B 187M 183M 7.96B
Net income	-64.92M -56.07M -51.67M -48.37M -90.64M -6.17B -92.04M -610M -238M -3B -244M -238M -10.4B	-51.69M -44.65M -41.14M -38.51M -72.17M -4.91B -73.29M -486M -189M -2.39B -194M -190M -8.28B
Net Debt	7.2M 6.22M 5.73M 5.36M 10.05M 684M 10.21M 67.67M 26.39M 333M 27.03M 26.45M 1.15B	12.95M 11.18M 10.3M 9.64M 18.07M 1.23B 18.35M 122M 47.44M 599M 48.59M 47.55M 2.07B

1 year	0		0
3 years	0		0.86
5 years	0		4.85
10 years	0		9.9